No price history available.
Key financial summary
Financials in ZAC| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | ZACm | 25,386 | 26,885 | 20,526 | 22,641 | 25,791 | 25,104 | N/A | N/A |
| Operating profit | ZACm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | ZACm | 38 | 1,754 | 1,531 | 264 | 4,827 | 3,864 | N/A | N/A |
| EPS reported | ZAC | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | ZAC | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | ZAC | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | ZAC | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | ZACm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | ZACm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | ZACm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | ZAC | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | ZAC | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in ZAC| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Headquartered in Johannesburg, South Africa, Life Healthcare Group Holdings Limited, established in 1983, operates as a prominent international provider of private hospital services. Its extensive operations span South Africa, Canada, the United Kingdom, various other European countries, and broader international markets. The company's business is structured into two principal divisions: Hospitals and Complementary Services, and Healthcare Services. It delivers a comprehensive range of acute hospital care alongside diverse complementary offerings. These include the specialized services of Life Esidimeni, which covers chronic mental healthcare, frail care, rehabilitation, step-down facilities, correctional healthcare, primary care, and substance abuse recovery programs. Additionally, its Life Employee Health Solutions segment provides on-site occupational health, primary healthcare, and employee wellness initiatives. The company's medical expertise extends across numerous fields, such as diagnostics, mental health treatment, acute rehabilitation, renal dialysis, oncology, cardiology, neurology, orthopedics, pediatrics, dermatology, ophthalmology, gynecology, and obstetrics. Furthermore, Life Healthcare is involved in advanced diagnostic imaging, operating magnetic resonance imaging (MRI) and computerized tomography (CT) scanners, and both developing and distributing radiopharmaceuticals vital for positron emission tomography-computerized tomography (PET-CT) diagnostics. The organization was formerly known as Afrox Healthcare Limited until its name change to Life Healthcare Group Holdings Limited in January 2005.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Life Healthcare Group Holdings Limited (LHC.JO)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Headquartered in Johannesburg, South Africa, Life Healthcare Group Holdings Limited, established in 1983, operates as a prominent international provider of private hospital services. Its extensive operations span South Africa, Canada, the United Kingdom, various other European countries, and broader international markets. The company's business is structured into two principal divisions: Hospitals and Complementary Services, and Healthcare Services. It delivers a comprehensive range of acute hospital care alongside diverse complementary offerings. These include the specialized services of Life Esidimeni, which covers chronic mental healthcare, frail care, rehabilitation, step-down facilities, correctional healthcare, primary care, and substance abuse recovery programs. Additionally, its Life Employee Health Solutions segment provides on-site occupational health, primary healthcare, and employee wellness initiatives. The company's medical expertise extends across numerous fields, such as diagnostics, mental health treatment, acute rehabilitation, renal dialysis, oncology, cardiology, neurology, orthopedics, pediatrics, dermatology, ophthalmology, gynecology, and obstetrics. Furthermore, Life Healthcare is involved in advanced diagnostic imaging, operating magnetic resonance imaging (MRI) and computerized tomography (CT) scanners, and both developing and distributing radiopharmaceuticals vital for positron emission tomography-computerized tomography (PET-CT) diagnostics. The organization was formerly known as Afrox Healthcare Limited until its name change to Life Healthcare Group Holdings Limited in January 2005.